Has the Hong Kong Pharma Industry valuation changed over the past few years?

Investors are optimistic on the Hong Kong Pharmaceuticals industry, and appear confident in long term growth rates. The industry is trading at a PE ratio of 21.7x which is higher than its 3-year average PE of 18.2x. The industry is trading close to its 3-year average PS ratio of 1.2x.

Which industries have driven the changes within the Hong Kong Healthcare industry?

There are no additional sub-industries under this industry.

Hong Kong (HSI) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 14 Jun 2026	HK$635.3b	HK$522.5b	HK$29.3b	13.1x	21.7x	1.2x
Tue, 12 May 2026	HK$736.1b	HK$520.2b	HK$30.1b	15x	24.5x	1.4x
Thu, 09 Apr 2026	HK$793.5b	HK$516.9b	HK$30.2b	15.3x	26.3x	1.5x
Sat, 07 Mar 2026	HK$762.4b	HK$498.1b	HK$30.4b	12.4x	25.1x	1.5x
Mon, 02 Feb 2026	HK$819.7b	HK$494.1b	HK$30.3b	13.3x	27.1x	1.7x
Wed, 31 Dec 2025	HK$780.6b	HK$489.7b	HK$30.0b	13x	26x	1.6x
Fri, 28 Nov 2025	HK$834.7b	HK$483.3b	HK$30.2b	13.5x	27.6x	1.7x
Sun, 26 Oct 2025	HK$777.6b	HK$480.2b	HK$30.1b	13.7x	25.8x	1.6x
Tue, 23 Sep 2025	HK$802.9b	HK$479.5b	HK$30.6b	13.8x	26.2x	1.7x
Thu, 21 Aug 2025	HK$783.2b	HK$477.2b	HK$31.2b	11.9x	25.1x	1.6x
Sat, 19 Jul 2025	HK$740.2b	HK$475.3b	HK$29.1b	12.7x	25.5x	1.6x
Mon, 16 Jun 2025	HK$666.8b	HK$476.7b	HK$28.8b	11.5x	23.1x	1.4x
Wed, 14 May 2025	HK$496.4b	HK$474.4b	HK$29.0b	10.9x	17.1x	1x
Fri, 11 Apr 2025	HK$461.5b	HK$464.6b	HK$28.5b	9.6x	16.2x	1x
Sun, 09 Mar 2025	HK$452.3b	HK$464.2b	HK$31.9b	8.6x	14.2x	1x
Tue, 04 Feb 2025	HK$410.1b	HK$464.7b	HK$32.0b	8.4x	12.8x	0.9x
Thu, 02 Jan 2025	HK$433.4b	HK$460.1b	HK$31.7b	8.6x	13.7x	0.9x
Sat, 30 Nov 2024	HK$444.3b	HK$463.1b	HK$31.5b	8.1x	14.1x	1x
Mon, 28 Oct 2024	HK$482.4b	HK$470.9b	HK$32.7b	7.9x	14.7x	1x
Wed, 25 Sep 2024	HK$449.4b	HK$477.4b	HK$33.1b	7.7x	13.6x	0.9x
Fri, 23 Aug 2024	HK$430.9b	HK$464.8b	HK$30.7b	6.9x	14x	0.9x
Sun, 21 Jul 2024	HK$430.5b	HK$457.8b	HK$32.5b	7.5x	13.2x	0.9x
Tue, 18 Jun 2024	HK$461.6b	HK$463.1b	HK$33.9b	8.3x	13.6x	1x
Thu, 16 May 2024	HK$488.4b	HK$464.0b	HK$33.8b	8.9x	14.5x	1.1x
Sat, 13 Apr 2024	HK$440.7b	HK$464.9b	HK$33.8b	7.6x	13x	0.9x
Mon, 11 Mar 2024	HK$439.1b	HK$470.9b	HK$33.5b	8x	13.1x	0.9x
Wed, 07 Feb 2024	HK$418.0b	HK$473.1b	HK$33.9b	6.7x	12.3x	0.9x
Fri, 05 Jan 2024	HK$489.9b	HK$472.2b	HK$33.7b	8.2x	14.5x	1x
Sun, 03 Dec 2023	HK$506.1b	HK$472.6b	HK$33.8b	7.5x	15x	1.1x
Tue, 31 Oct 2023	HK$483.0b	HK$469.0b	HK$31.5b	6.7x	15.3x	1x
Thu, 28 Sep 2023	HK$438.8b	HK$469.1b	HK$31.5b	6.8x	13.9x	0.9x
Sat, 26 Aug 2023	HK$424.2b	HK$448.9b	HK$30.7b	7.8x	13.8x	0.9x
Mon, 24 Jul 2023	HK$475.5b	HK$446.5b	HK$27.9b	9x	17.1x	1.1x
Wed, 21 Jun 2023	HK$511.3b	HK$446.9b	HK$27.7b	9.6x	18.5x	1.1x


HK Market	0.19%
Healthcare	-1.00%
Pharma	0.45%
Pharma	0.45%

Company	Last Price	7D	1Y	Valuation
3692 Hansoh Pharmaceutical Group	HK$29.98	2.3% +HK$4.0b	2.0%	PE28.2x
6872 TenNor Therapeutics (Suzhou)	HK$262.20	21.7% +HK$2.4b	n/a	PB76.1x
867 China Medical System Holdings	HK$11.00	3.3% +HK$847.2m	-2.8%	PE15.4x
1177 Sino Biopharmaceutical	HK$4.70	0.9% +HK$713.2m	-15.0%	PE30.9x
3320 China Resources Pharmaceutical Group	HK$4.84	2.3% +HK$691.1m	-8.7%	PE6.5x

Announcement • May 30

Sino Biopharmaceutical Limited Presents Data From Two Phase III Clinical Trials Of Bepirovirsen At EASL 2026

Sino Biopharmaceutical Limited announced that positive pivotal data for bepirovirsen, jointly developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and GSK plc, for the treatment of chronic hepatitis B was presented. The results from two Phase III clinical trials, B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820), were simultaneously published in the New England Journal of Medicine and presented at the 2026 European Association for the Study of the Liver Congress. The data on regional subgroups was also presented in an oral session at the EASL. In particular, the data from the Chinese subgroup showed that among subjects with HBsAg = 3000 IU/ml, the functional cure rate was 24%; among subjects with HBsAg = 1000 IU/ml, the functional cure rate reached 35%. The results from the two trials are summarised as follows: Functional cure rates at Week 72 in B-Well 1 and B-Well 2 by patient segment: Functional cure response rate at Week 72 of the B-Well trials, 6 months after discontinuing all treatments: Primary confirmatory endpoint: 19% vs. 0% (placebo) 233 of 1,220 vs. 0 of 614; B-Well 1: 20% vs. 0% [127 of 650 vs. 0 of 328]; B-Well 2: 19% vs. 0% [106 of 570 vs. 0 of 286]. Ranked secondary endpoint: 26% vs. 0% (placebo) 200 of 768 vs. 0 of 393; B-Well 1: 25% vs. 0% [105 of 426 vs. 0 of 214]; B-Well 2: 28% vs. 0% [95 of 342 vs. 0 of 179]. Pooled data from both trials showed that 6-month treatment with bepirovirsen achieved a statistically significant and clinically meaningful 19% functional cure response rate (233 of 1,220 vs. 0 of 614 in the placebo group, with p<0.001 in both trials) in the overall study population (adults with =3000 IU/ml hepatitis B surface antigen (HBsAg) level), meeting the primary endpoint. In a key secondary endpoint, a functional cure rate of 26% (200 of 768 vs. 0 of 393 in the placebo group, with p < 0.001 in both trials) was achieved in participants with = 1,000 IU/ml HBsAg level, a group that represents approximately 45% of diagnosed chronic hepatitis B cases globally. The current standard of care typically requires lifelong therapy, with functional cure rates achieved in less than 1% of patients. Functional cure occurs when the hepatitis B virus DNA and HBsAg are undetectable in the blood for at least 6 months after stopping all treatments. This indicates the disease is controlled by the immune system without medication. A loss in HBsAg is also associated with an 89% reduction in risk of liver cancer and a 62% reduction in risk of all-cause mortality. Notably, in an exploratory analysis, 49% of bepirovirsen recipients achieved a quantitative hepatitis B surface antigen of =100 IU/mL one year after the end of treatment. Medical literature has linked this level of low surface antigen with increased immune control and improved patient outcomes. Moreover, 23% of all bepirovirsen recipients (283 of 1,220 vs. 0 of 614 in the placebo group; p<0.001 in both trials) and 31% of bepirovirsen recipients with baseline HBsAg =1000 IU/mL (237 of 768 vs. 0 of 393 in the placebo group; p<0.001 in both trials) achieved a sustained hepatitis B virus DNA lower limit of quantification (<LLOQ) at Week 72 after stopping all treatments at Week 48 in a key secondary endpoint. Bepirovirsen arm received bepirovirsen plus standard of care, placebo arm received placebo plus standard of care. Defined as HBsAg not detected (quantitative; < 0.05 IU/mL) and hepatitis B virus DNA < LLOQ (< 20 IU/mL or target not detected). The absolute values are being presented bepirovirsen group vs. placebo group. The trials showed an acceptable safety and tolerability profile consistent with other studies of bepirovirsen. The three most frequently observed adverse events were injection site erythema, local pain and temporary rise in the blood level of a liver enzyme. Bepirovirsen is currently under review by regulatory authorities in China (Breakthrough Therapy and Priority Review designation granted), the United States (Priority review, Breakthrough Therapy and Fast Track Designation granted), Europe, and Japan (SENKU designation granted). GSK anticipates to receive the regulatory decision from the China’s National Medical Products Administration in the first half of 2027, and launch preparations are underway. The B-Well 1 and B-Well 2 trials are global multi-centre, randomised, double-blind, placebo-controlled trials conducted in 29 countries. They assessed the efficacy, safety, pharmacokinetic profile and durability of functional cure in nucleos(t) ide analogue-treated adult participants with chronic hepatitis B and baseline surface antigen (HBsAg) =3000 IU/ml. The primary endpoint assessed the proportion of participants achieving functional cure in patients with baseline HBsAg =3000 IU/ml. A key ranked secondary endpoint evaluated functional cure in participants with baseline HBsAg =1000 IU/ml. Functional cure is defined as HBsAg being undetectable in the blood for at least 24 weeks after stopping all treatments, indicating that the disease is controlled by the immune system without medication.

Hong Kong (HSI) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

United Laboratories Advances Autoimmune Drug Trials and Launches HK$200 Million Buyback

Simcere Pharmaceutical Partners With Stanford Medicine on Potential New Therapy for Pulmonary Fibrosis

Tennor Therapeutics (Suzhou) Limited Appoints Song Gaoguang as Member of Remuneration and Appraisal Committee, Effective June 8, 2026

Upcoming dividend of HK$0.14 per share

China Medical System Highlights Progress on siRNA Obesity Drug at Leading Diabetes Conference

Consun Pharmaceutical Group Invests RMB 191.4 Million for 30% Stake in Shanghai Huamao

Grand Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2025

Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 26, 2026

Investor sentiment deteriorates as stock falls 15%

CF PharmTech, Inc., Annual General Meeting, Jun 26, 2026

Sino Biopharmaceutical Limited Presents Data From Two Phase III Clinical Trials Of Bepirovirsen At EASL 2026

Xuanzhu Biopharmaceutical Co., Ltd., Annual General Meeting, Jun 18, 2026

Full year 2025 earnings released: CN¥0.38 loss per share (vs CN¥0.43 loss in FY 2024)

Modern Chinese Medicine Group Co., Ltd., Annual General Meeting, May 29, 2026

Full year 2025 earnings released: CN¥2.33 loss per share (vs CN¥1.45 loss in FY 2024)

Full year 2025 earnings: EPS misses analyst expectations